Fig. 1.

qHTS of NPC drug library. A, Enrichment analysis of active agents in each drug category. To determine whether the active compounds were predominantly identified from a certain therapeutic category, we performed an enrichment analysis of the drug library. The 2816 compounds in the NPC collection were classified into different therapeutic categories based on their pharmaceutical indications. The red dashed line indicates enrichment ratio of greater than 20% in the category of active drugs. B, The comparison of antiproliferative activity of each drug in normal and cancer cell lines and primary culture of chronic lymphocytic leukemia cells. NFκB is a cervical cancer cell line; Mrc5 is a lung tissue cell line, fetus, normal; messangial is a kidney cell line, normal; Uch and ccl4b is a chordoma, tumor from bone in skull base or spine; Lam is a lung smooth muscle proliferation, benign tumor, human patient cell line; and CLL is a chronic lymphocytic leukemia. Each compound was converted into an integer that represents its activity outcome in each cell viability assay. Integer 1 represents compounds in the active category, which corresponds to red in the heatmap. Integer 2 represents compounds in the inconclusive category, which corresponds to light red in the heatmap. If a compound didn't show any activity in an assay, integer 3 was assigned to such category, indicated as white in the heatmap. Compounds not tested in a cell line assay were labeled as 4 and are represented as gray in the heatmap. Different activity outcomes were observed from each cell viability assay, and the compounds were categorized based on the similarity metric derived from the activity profiles.